RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases

Current Opinion in Investigational Drugs

Volumn 11, Issue 3, 2010, Pages 357-364

  McNeill, E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; QUINAZOLINONE DERIVATIVE; RESVERATROL; RVX 208; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ATHEROSCLEROSIS; BIOEQUIVALENCE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; LOW DRUG DOSE; NONHUMAN; PATENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; TRANSCRIPTION INITIATION;

ANIMALS; APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION; HUMANS; QUINAZOLINES;

EID: 77649168189     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA CIRCULATION 1989 79 1 8-15
2. Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns. Franceschini G, Sirtori CR, Bosisio E, Gualandri V, Orsini GB, Mogavero AM, Capurso A ATHEROSCLEROSIS 1985 58 1-3 159-174
3. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Franceschini G, Calabresi L, Chiesa G, Parolini C, Sirtori CR, Canavesi M, Bernini F ARTERIOSCLER THROMB VASC BIOL 1999 19 5 1257-1262
4. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B CIRCULATION 1998 97 8 780-785
5. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S et al JAMA-J AM MED ASSOC 2003 290 17 2292-2300
6. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR AM J MED 1977 62 5 707-714
7. Annual information form. Resverlogix Corp ANNUAL REPORT 2004 December 03
8. In interests of patient safety, Pfizer stops all torcetrapib clinical trials; company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities. Pfizer Inc PRESS RELEASE 2006 December 02
9. Resverlogix RVX-208 passes key toxicology milestone. Resverlogix Corp PRESS RELEASE 2007 March 07
10. Effects of torcetrapib in patients at high risk for coronary events. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J, Waters DD, Shear CL et al N ENGL J MED 2007 357 21 2109-2122
11. Use of RVX-208 to increase apolipoprotein A-I and HDL in animals and phase I clinical trials. Johansson J, Jahagirdar R, Genest J, Krimbou L, Chiacchia F, Wagner G, Hansen H, McLure KG, Wong NC ARTERIOSCLER THROMB VASC BIOL 2008 28 6 Abs E32
12. Tredaptive (nicotinic acid /laropiprant) approved in the European Union: New lipid-modifying therapy to treat LDL-C, HDL-C and triglycerides. Merck & Co Inc PRESS RELEASE 2008 July 11
13. NCT00768274: Safety, pharmacokinetic study of RVX000222 in healthy subjects and subjects with low HDL cholesterol. Resverlogix Corp www.clinicaltrials.gov 2007
14. Compound RVX-208 modulates HDL-C levels and function in non-human primates and in early (phase I) human trials. Krimbou L, Jahagirdar R, Bailey D, Hafiane A, Ruel I, Wong N, Wagner GS, Chiacchia F, Gordon A, Hansen HC, Johansson J et al CIRCULATION 2008 118 18S Abs 1696
15. RVX-208 exploratory study illustrates early potential for Alzheimer's disease. Resverlogix Corp PRESS RELEASE 2008 November 10
16. RVX-208 a small molecule that induces apolipoprotein A-I production progresses to phase Ib/IIa clinical trials. Gordon A, Jahagirdar R, Johansson J, Wagner G, Bailey D, Hansen H, McLure K, Krimbou L, Genest J, Wong NCW J AM COLL CARDIOL 2009 53 10 Suppl 1 Abs 1021-1074
17. Resverlogix provides quarterly update. Resverlogix Corp PRESS RELEASE 2009 April 28
18. American College of Cardiology-58th annual scientific session. Wong NCW IDRUGS 2009 12 5 291-293
19. Inflammation, atherosclerosis, and coronary artery disease. Hansson GK N ENGL J MED 2005 352 16 1685-1695
20. Resverlogix phase 1b/2a study meets primary endpoint. Resverlogix Corp PRESS RELEASE 2009 August 25
21. Resverlogix RVX-208 second clinical trial demonstrates success on key reverse cholesterol transport markers. Resverlogix Corp PRESS RELEASE 2009 September 29
22. Oral administration of compound RVX-208 increases serum levels of apoA-I and improves high-density lipoproteinmediated cholesterol efflux in African green monkeys. Krimbou L, Jahagirdar R, Ruel I, Johansson J, Genest J CIRCULATION 2007 116 16 Abs 679
23. RVX-208, a small molecule increases apolipoprotein A-I, pre-? HDL, and mature HDL in humans. Gordon A, Johansson J, Chiacchia F, Jahagirdar R, Wagner G, Bailey D, Hansen H, Krimbou L, Genest J, Wong NC ARTERIOSCLER THROMB VASC BIOL 2009 29 7 Abs P301
24. RVX-208 a novel small molecule that increases apolipoprotein A-I enters into human clinical trials. Johansson J, Jahagirdar R, Genest J, Krimbou L, Chiacchia F, Wagner GS, Hansen HC, McLure KG, Wong NCW EUR HEART J 2008 29 Suppl 1 Abs 1131
25. RVX-208: A small molecule that increases APOA-I, HDL-C, and cholesterol efflux. Jahagirdar R, Genest J, Hansen HC, Nicholls CD, Attwell S, McLure KG, Wagner GS, Johansson J, Wong NCW ATHEROSCLEROSIS SUPPL 2008 9 1 Abs WO2-OR5
26. A novel drug RVX-208 raises plasma apolipoprotein A-I and HDL cholesterol. Jahahirdar R, Nicholls DC, Hansen CH, Attwell S, McClure KG, Wagner GS, Johansson J, Wong NCW J CLIN LIPIDOL 2007 1 5 Abs 23
27. RVX-208 a small molecule increases APOA-I, preBHDL, and functionality of HDL in humans. Gordon A, Jahagirdar R, Johansson V, Chiacchia F, Hansen H, Wagner G, Bailey D, Krimbou L, Genest J, Wong N ATHEROSCLEROSIS SUPPL 2009 10 2 Abs 1453
28. RVX-208 increases APOA-I, pre-B-HDL, HDL functionality and inhibits markers of inflammation. A Gordon, S Attwell, R Jahagirdar, N Wong ATHEROSCLEROSIS SUPPL 2009 10 2 Abs S4-2
29. Resverlogix updates shareholders on accelerated clinical trial plan. Resverlogix Corp PRESS RELEASE 2009 October 16
30. Merck's investigational anacetrapib phase IIb study results presented at American Heart Association Annual Scientific Sessions. Merck & Co Inc PRESS RELEASE 2009 November 17
31. Coronary artery disease-Eighth international congress. From prevention to intervention. Wong NCW IDRUGS 2009 12 12 742-746
32. American Heart Association Scientific Sessions, in brief. FDC REP PINK SHEET 2009 71 47 17-18
33. Resverlogix commences phase 2 Atherosclerosis clinical trial. Resverlogix Corp PRESS RELEASE 2009 December 22
34. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W LANCET 1999 354 9186 1234-1241
35. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Faggiotto A, Ross R, Harker L ARTERIOSCLEROSIS 1984 4 4 323-340 (Pubitemid 14092676)
36. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, de Craen AJM, Knopp RH, Nakamura H, Ridker P, van Domburg R et al BR MED J 2009 338 June 30 doi: 10.1136/bmj.b2376
37. High-density lipoproteins, inflammation and oxidative stress. Tabet F, Rye KA CLIN SCI 2009 116 1-2 87-98
38. The metabolism and anti-atherogenic properties of HDL. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ J LIPID RES 2009 50 Suppl S195-S200
39. Promoting mechanisms of vascular health circulating progenitor cells, angiogenesis, and reverse cholesterol transport. Moreno PR, Sanz J, Fuster V J AM COLL CARDIOL 2009 53 25 2315-2323
40. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H, Nilsson J CIRCULATION 1994 90 4 1935-1941
41. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Kaul S, Rukshin V, Santos R, Azarbal B, Bisgaier CL, Johansson J, Tsang VT, Chyu KY, Cercek B, Mirocha J, Shah PK CIRCULATION 2003 107 20 2551-2554
42. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, Grijalva VR, Ganesh VK, Mishra VK, Palgunachari MN, Fogelman AM CIRC RES 2005 97 6 524-532
43. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Jin FY, Kamanna VS, Kashyap ML ARTERIOSCLER THROMB VASC BIOL 1997 17 10 2020-2028
44. Update on strategies to increase HDL quantity and function. Duffy D, Rader DJ NAT REV CARDIOL 2009 6 7 455-463
45. Basic aspects of plaque vulnerability. Lafont A HEART 2003 89 10 1262-1267
46. Pathophysiology of coronary artery disease. Libby P, Theroux P CIRCULATION 2005 111 25 3481-3488
47. Targeting residual cardiovascular risk: Raising highdensity lipoprotein cholesterol levels. Hausenloy DJ, Yellon DM POSTGRAD MED J 2008 84 997 590-598
48. -2009 annual report. Resverlogix Corp ANNUAL REPORT 2010 October 15
49. Two-dimensional electrophoresis of plasma lipoproteins: Recognition of new apo A-I-containing subpopulations. Asztalos BF, Sloop CH, Wong L, Roheim PS BIOCHIM BIOPHYS ACTA 1993 1169 3 291-300
50. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A et al CIRCULATION 2009 December 17doi: 10.1161/circulationaha.109.192667